Orphan Drug Companies Warned To Beware Of The Dutch Lock System
Executive Summary
Companies selling orphan medicines in the Netherlands need to prepare for the likelihood that their products will enter the so-called lock system, which means they will come under extra scrutiny and take longer to reach patients.
You may also be interested in...
Dutch Minister Demands ‘Socially Acceptable’ Price For Gilead’s Trodelvy
Gilead’s breast cancer drug Trodelvy is too expensive for the benefits it offers and will not be reimbursed in the Netherlands unless the company drops its price, said the Dutch health minister.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.